Biocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...

The EMA's Committee for Medicinal Products for Human Use (CHMP) opinion will be considered by the European Commission. "The European Commis...

BBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...

The business of the joint venture will be kickstarted with the launch of human insulin in the fourth quarter of FY22.

Biocon said the CHMP positive opinion will be considered by the European Commission. The European Commission decision on the approval is ex...

It is all about reaching our $1billion revenue target by FY22 and to reach 5 million patients by end of 2022, says Christiane Hamacher.

The biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologi...

Herceptin is a biosimilar trastuzumab is going to be a major launch for both Biocon & Mylan.

The Biocon subsidiary will chart a path that ensures high volumes and low costs, unlike competitors. The company plans to create an ecosyst...

The integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...

The drug, manufactured by Biocon at its large scale biopharmaceutical facility in Johor, Malaysia, is the country's first locally manufactu...

"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...

Biocon is altering its product commercialisation strategy by eyeing to partner with many regional players rather than joining hands with a ...

Bangalore-based Biocon is planning to forge partnerships as well as leverage existing alliances to augment the access and penetration of it...

As per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these...

The agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...

The deal will enable the Bangalore-based player to market its injectible insulin, generics, biosimilars and biologics in Europe.